A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. |
18349277 |
Cancer Epidemiol Biomarkers Prev |
Blood and urine markers for ovarian cancer: a comprehensive review. |
15322314 |
Dis Markers |
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. |
15894662 |
Cancer Epidemiol Biomarkers Prev |
Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. |
12912935 |
Clin Cancer Res |
Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. |
14581349 |
Clin Cancer Res |
Non-genomic biomarkers of risk in ovarian cancer. |
18057519 |
Dis Markers |
Osteopontin as a potential diagnostic biomarker for ovarian cancer. |
11926891 |
JAMA |
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. |
15161704 |
Clin Cancer Res |
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. |
21372036 |
Cancer Prev Res (Phila) |
Pooling of case specimens to create standard serum sets for screening cancer biomarkers. |
17301268 |
Cancer Epidemiol Biomarkers Prev |
Promoter hypermethylation profile of ovarian epithelial neoplasms. |
16061849 |
Clin Cancer Res |
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. |
11584061 |
J Natl Cancer Inst |
Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer. |
17245808 |
J Bioinform Comput Biol |
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. |
16428483 |
Clin Cancer Res |
Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. |
19008269 |
BMJ |
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). |
19282241 |
Lancet Oncol |
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. |
18061248 |
Gynecol Oncol |
Urokinase-type plasminogen activator receptor: a beacon of malignancy? |
18794069 |
Clin Cancer Res |
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. |
18245537 |
Clin Cancer Res |